Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (774)	5/7/1998 2:31:00 PM
From: InvestorLady	Respond to of 1491

David, true, young companies tend to know little about PR, but I thought they hired someone new. Do you know if that person did this release? Small companies have SUCH a hard time getting DOW to pick up stories (not reuters which brokers generally do not get, vast majority only have DOW headers/stories on their machines). They really do need to work at it harder. Glad to hear there is improvement, but they ain't there yet. Lady

To: David Israel-Rosen who wrote (774)	5/7/1998 4:43:00 PM
From: Ariella	Read Replies (1) \| Respond to of 1491

Today's PARS release did some fine things -- it presented the product pipeline in the proper order of interest to investors -- drugs rolling out to the public next month (Alrex and Lotemax), followed by most advanced clinical trial drug (HU-211), and then most important pre-clinical trial drug (Tamoxifen analog). Critical investment news about the low mortality rates on HU-211 was presented to the investment public for possibly the first time. If memory serves me right, the mortality figures are not even disclosed in recent SEC documents. Yes, the release has that clipped, compressed style of Hebrew speech (that "we-have-our-heads-above-the-foxhole-and-someone -is- shooting-at-us-so-we-better-talk-quick" quality), but as a sizeable block shareholder, I am pleased. Our story is being amplified in GLOBES and Ha'Aretz, so the PR buck goes farther than it seems. Also, in a way I'm glad this comes a bit slowly. PARS management needs to get its "sea legs" for the coming blast of interest in HU-211 when it gets a big pharmaceutical partner. In the meantime I don't want their attention monopolized by callers asking questions about early stage drugs. Going from an early-stage company to a small cap (hopefully bigger cap!) is like blasting off in a rocket and it's better if they're prepared so we can actually make it into orbit. On the question of additional funds required -- It would be very worthwhile for PARS to talk to some venture capital funds that specialize in early stage biotech companies. Not only will they be long-term players in the stock (unlike our current big pockets who are, let's face it, on the cut-throat side), but they will have excellent connections to the rest of the financial world. Word gets out by more than press releases on Wall Street! Nothing beats word-of-mouth from excellent sources with good track records. Here are two examples, the first a wing of the Rockefeller Family: www.venrock.com www.paramountcapital.com If we're at too advanced a stage for these folks, the visits can still be fruitful. PARS management can get several benefits from talking to these types of companies besides the potential for investment. It's practice for talking to stock market analysts later on, it's practice getting the right "spin" on the PHARMOS story, it gets word out about the company even before any deals are struck, it puts PARS on the map.